Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Ava Amidei, Benjamin Diamond, Elizabeth Lyubchenko, Stephanie Fernandes, Bahar Fard, Lubna Nousheen, Marc Arribas-Layton, Adam Sciambi, Dickran Kazandjian, James Hoffman, Abhishek Pandey, Marcella Kaddoura, Brian Walker, Ola Landgren, David Coffey

Blood (2025) 146 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2025-2157

Published: 2025

Journal Articles

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Blood (2025) 146 (Supplement 1): 7483.

https://doi.org/10.1182/blood-2025-7483

Published: 2025

Journal Articles

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

Blood (2025) 146 (Supplement 1): 7479.

https://doi.org/10.1182/blood-2025-7479

Published: 2025

Journal Articles

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Blood (2025) 146 (Supplement 1): 251.

https://doi.org/10.1182/blood-2025-251

Published: 2025

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Blood (2025) 146 (Supplement 1): 247.

https://doi.org/10.1182/blood-2025-247

Published: 2025

Journal Articles

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Enze Liu, Nathan Becker, Sreejeta Mondal, Attaya Suvannasankha, David Coffey, Benjamin Diamond, Abhishek Pandey, Kelvin Lee, Dickran Kazandjian, Rafat Abonour, Aneta Mikulasova, Gareth Morgan, Ola Landgren, Brian Walker

Blood (2025) 146 (Supplement 1): 5693.

https://doi.org/10.1182/blood-2025-5693

Published: 2025

Journal Articles

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Nathan Becker, Enze Liu, Zackary Sanborn, Attaya Suvannasankha, Kelvin Lee, Dickran Kazandjian, James Hoffman, Benjamin Diamond, Abhishek Pandey, Rafat Abonour, Ola Landgren, Lisa Munding, Aneta Mikulasova, Brian Walker

Blood (2025) 146 (Supplement 1): 3928.

https://doi.org/10.1182/blood-2025-3928

Published: 2025

Journal Articles

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Ola Landgren, Benjamin Diamond, Abhishek Pandey, James Hoffman, David Coffey, Marcella Kaddoura, Brian Walker, Rabia Bukhari, Caterine Diaz, Stephanie Mompoint, Sindy Gutierrez, Kellye Koubek, Andrew Kowalski, Leslie Gallardo, Stephanie Fernandes, Sandra Mira, Massiel Cardo Lopez, Michelle Armogan, Dickran Kazandjian

Blood (2025) 146 (Supplement 1): 5775.

https://doi.org/10.1182/blood-2025-5775

Published: 2025

Journal Articles

The importance of MRI in diagnostic workup of smoldering multiple myeloma

Roshani Patel, Baris Turkbey, Peter Choyke, Dickran Kazandjian, Elizabeth Hill

Blood (2025) 146 (Supplement 1): 5767.

https://doi.org/10.1182/blood-2025-5767

Published: 2025

Journal Articles

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes

Blood (2025) 146 (Supplement 1): 2518.

https://doi.org/10.1182/blood-2025-2518

Published: 2025

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Blood (2025) 146 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2025-3920

Published: 2025

Journal Articles

Direct thrombin inhibition by paraprotein in multiple myeloma: A rare mechanism of paraprotein-mediated coagulopathy, corrected with myeloma therapy

Tessa Lavorgna, Thomas Plate, Dickran Kazandjian, Gerald Soff

Blood (2025) 146 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2025-1306

Published: 2025

Journal Articles

Monoclonal gammopathy-related coagulopathies: A systematic analysis

Tessa Lavorgna, Thomas Plate, Diana Byrnes, Dickran Kazandjian, Benjamin Diamond, James Hoffman, Ola Landgren, Gerald Soff

Blood (2025) 146 (Supplement 1): 1305.

https://doi.org/10.1182/blood-2025-1305

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Blood (2024) 144 (Supplement 1): 496.

https://doi.org/10.1182/blood-2024-205083

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

The importance of MRI in diagnostic workup of smoldering multiple myeloma

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Direct thrombin inhibition by paraprotein in multiple myeloma: A rare mechanism of paraprotein-mediated coagulopathy, corrected with myeloma therapy

Monoclonal gammopathy-related coagulopathies: A systematic analysis

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only